Cardiology journal最新文献

筛选
英文 中文
Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study. 经导管主动脉瓣植入降低血浆TMAO和硫酸吲哚酚浓度:一项前瞻性、多中心队列研究。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2025-03-10 DOI: 10.5603/cj.102844
Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal
{"title":"Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study.","authors":"Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal","doi":"10.5603/cj.102844","DOIUrl":"10.5603/cj.102844","url":null,"abstract":"<p><strong>Background: </strong>Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic valve implantation (TAVI) on these intestinal bacterial metabolites has not been evaluated in a multicenter clinical study. The aim of this study was to determine the effect of TAVI on plasma levels of intestinal bacterial metabolites and to assess the predictive value of these metabolites for major adverse cardiovascular events (MACE) following TAVI. M: ETHODS: Consecutive patients with AS referred for TAVI were enrolled in this study. Blood samples were collected one day before TAVI and at hospital discharge. The concentrations of intestinal microbial metabolites were measured using ultra performance liquid chromatograph coupled with a mass spectrometer.</p><p><strong>Results: </strong>Plasma levels of TMAO and IS decreased after TAVI, compared to baseline (p ≤ 0.004 for all). Among 128 patients included in the study, 21 patients (16.4%) developed MACE during the median follow-up time of 404 days. Baseline plasma IS level was higher in patients with MACE, compared to those without MACE (p = 0.001). Increased baseline IS level predicted MACE with 75.0% sensitivity and 74.3% specificity independent of other clinical variables (OR 14.264, 95% CI 3.442-59.117, p < 0.001) and decreased the chance of event-free survival (plog rank < 0.001).</p><p><strong>Conclusions: </strong>Plasma concentrations of TMAO and IS decreased after TAVI, compared to baseline. Elevated plasma IS levels were associated with a 14-fold increase in the odds of post-TAVI MACE during a median follow-up period of 404 days.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"164-174"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Silent cerebral ischemic lesions in ablation-naïve patients with non-valvular atrial fibrillation: Does the pulmonary vein anatomy matter? 未经消融治疗的非瓣膜性心房颤动患者的无声脑缺血病变:肺静脉解剖结构是否重要?
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.5603/cj.99142
Andrzej Głowniak, Anna Drelich-Zbroja, Adam Tarkowski, Paweł Marzęda, Katarzyna Wojewoda, Katarzyna Wysokińska, Anna Wysocka, Monika Miazga, Anna Jaroszyńska, Krzysztof Kaczmarek, Andrzej Jaroszyński, Michał Orczykowski
{"title":"Silent cerebral ischemic lesions in ablation-naïve patients with non-valvular atrial fibrillation: Does the pulmonary vein anatomy matter?","authors":"Andrzej Głowniak, Anna Drelich-Zbroja, Adam Tarkowski, Paweł Marzęda, Katarzyna Wojewoda, Katarzyna Wysokińska, Anna Wysocka, Monika Miazga, Anna Jaroszyńska, Krzysztof Kaczmarek, Andrzej Jaroszyński, Michał Orczykowski","doi":"10.5603/cj.99142","DOIUrl":"10.5603/cj.99142","url":null,"abstract":"<p><strong>Background: </strong>Silent cerebral ischemic lesions (SCILs) detected by magnetic resonance imaging (MRI) can precede symptomatic stroke, the risk of which is increased five-fold in atrial fibrillation (AF) patients. In our study, we aimed to evaluate the initial incidence of SCILs in the population of patients referred for ablation due to symptomatic AF and to identify possible risk factors.</p><p><strong>Methods: </strong>A total of 110 patients, with a mean age (SD) of 59.9 (9.4) years, referred for ablation, were included in the study. In all patients, MRI was performed before the procedure to evaluate the incidence of SCILs in the ablation-naïve patients.</p><p><strong>Results: </strong>MRI revealed preexisting SCIL in 81/110 patients (73.6%). Notably, SCILs were found in all patients with CHA₂DS₂-VASc score ≥ 4. In univariable analysis, age (p < 0.001), CHA₂DS₂-VASc score (p = 0.001), hypertension (p = 0.01), and anticoagulation duration (p = 0.023) were identified as significant risk factors for SCILs, while the presence of anatomical variants of left-sided common pulmonary veins trunk (LCPV) had negative prognostic value (p = 0.026). Multivariable logistic regression analysis identified age (p < 0.001) as the risk factor of preexisting SCILs, whereas the presence of LCPV trunk was associated with significantly lower (p = 0.005) SCILs incidence.</p><p><strong>Conclusions: </strong>Silent cerebral ischemic lesions detected in MRI are frequent in the population of patients with non-valvular AF. The incidence of SCILs is higher in patients with long history of arrhythmia and higher CHA₂DS₂-VASc score. The relationship between the anatomy of pulmonary veins and the incidence of SCILs needs further investigation.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"35-42"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis. 胱抑素C在急性冠脉综合征中的诊断和预后价值:一项最新的荟萃分析。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2025-02-20 DOI: 10.5603/cj.102453
Michal Pruc, Damian Swieczkowski, Basar Cander, Milosz J Jaguszewski, Sagar Galwankar, Salvatore Di Somma, Fatimah Lateef, Indrani Sardesai, Ayman El-Menyar, Michal Zembala, Jacek Kubica, Togay Evrin, Burak Katipoglu, Zubaid Rafique, Frank William Peacock, Lukasz Szarpak
{"title":"Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis.","authors":"Michal Pruc, Damian Swieczkowski, Basar Cander, Milosz J Jaguszewski, Sagar Galwankar, Salvatore Di Somma, Fatimah Lateef, Indrani Sardesai, Ayman El-Menyar, Michal Zembala, Jacek Kubica, Togay Evrin, Burak Katipoglu, Zubaid Rafique, Frank William Peacock, Lukasz Szarpak","doi":"10.5603/cj.102453","DOIUrl":"10.5603/cj.102453","url":null,"abstract":"<p><strong>Background: </strong>The role of Cystatin C (CysC) in the diagnosis and prognosis of cardiovascular disease, particularly acute coronary syndrome (ACS), is increasingly significant. The goal of this meta-analysis was to assess the diagnostic and prognostic value of CysC in patients with ACS, as well as its association with major adverse cardiovascular events (MACE), defined as mortality, myocardial infarction, heart failure, and stroke.</p><p><strong>Methods: </strong>The present study is a systematic review and meta-analysis. Using PubMed, Web of Science, Cochrane Library, and Embase, a literature review of cohort and case control studies reporting MACE and using the terms ACS and Cystatin C was conducted, excluding studies published after August 1, 2024. the meta-analysis using a random effects model.</p><p><strong>Results: </strong>CysC concentrations were significantly higher in patients with ACS compared to controls [mean difference (MD) = 0.36, p < 0.001], and in acute myocardial infarction (AMI) vs. unstable angina (MD = 0.18, p < 0.001). No significant differences were observed between ST elevation myocardial infarction (STEMI) and Non-ST elevation myocardial infarction (NSTEMI). Patients with MACE had higher CysC levels than those without (MD = 0.25, p < 0.001). Hospital survivors had lower CysC levels compared to those who died (MD = -0.25, p < 0.001). Higher CysC concentrations were associated with increased risks of MACE, cardiac death, overall mortality, myocardial reinfarction, and stroke, both during hospitalization and beyond.</p><p><strong>Conclusions: </strong>CysC is a promising biomarker for both diagnosis and prognosis in patients with ACS, especially in the context of predicting MACE, mortality and heart failure risk. The use of CysC may improve risk stratification and support therapeutic decision-making in clinical practice.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"142-152"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary cardiac angiosarcoma: an extremely rare entity presenting with palpitations. 原发性心脏血管肉瘤:一种以心悸为表现的极为罕见的疾病。
Cardiology journal Pub Date : 2025-01-01 DOI: 10.5603/cj.101335
Yueli Wang, Dong Chen, Jingjing Meng, Jiancheng Han, Yihua He
{"title":"Primary cardiac angiosarcoma: an extremely rare entity presenting with palpitations.","authors":"Yueli Wang, Dong Chen, Jingjing Meng, Jiancheng Han, Yihua He","doi":"10.5603/cj.101335","DOIUrl":"https://doi.org/10.5603/cj.101335","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 2","pages":"208-209"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint. 急性冠脉综合征患者在康格瑞洛后使用P2Y12受体抑制剂进行维持治疗。ELECTRA-SIRIO 2调查人员的观点。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2025-01-08 DOI: 10.5603/cj.98323
Jacek Kubica, Piotr Adamski, Robert Gajda, Aldona Kubica, Małgorzata Ostrowska, Gavino Casu, Diana A Gorog, Paul A Gurbel, Tomasz Hajdukiewicz, Miłosz Jaguszewski, Young-Hoon Jeong, Agata Kosobucka-Ozdoba, Zuzana Motovska, Piotr Niezgoda, Maciej Piasecki, Przemysław Podhajski, Paolo Raggi, Uzeyir Rahimov, Jolanta M Siller-Matula, Grzegorz Skonieczny, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Eliano P Navarese
{"title":"Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint.","authors":"Jacek Kubica, Piotr Adamski, Robert Gajda, Aldona Kubica, Małgorzata Ostrowska, Gavino Casu, Diana A Gorog, Paul A Gurbel, Tomasz Hajdukiewicz, Miłosz Jaguszewski, Young-Hoon Jeong, Agata Kosobucka-Ozdoba, Zuzana Motovska, Piotr Niezgoda, Maciej Piasecki, Przemysław Podhajski, Paolo Raggi, Uzeyir Rahimov, Jolanta M Siller-Matula, Grzegorz Skonieczny, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Eliano P Navarese","doi":"10.5603/cj.98323","DOIUrl":"10.5603/cj.98323","url":null,"abstract":"<p><p>According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The aim of this review is to summarize available evidence on the optimal maintenance therapy with P2Y12 receptor inhibitor after cangrelor. Transitioning from cangrelor to a thienopyridine, but not ticagrelor, can be associated with a drug-drug interaction (DDI); therefore, a ticagrelor loading dose (LD) can be given any time before, during, or at the end of a cangrelor infusion, while a LD of clopidogrel or prasugrel should be administered at the time the infusion of cangrelor ends or within 30 minutes before the end of infusion in the case of a LD of prasugrel. Administration of any oral antiplatelet agent at the end of a cangrelor infusion will also result in a transient period of increased platelet reactivity. The inter-individual variability of this period is difficult to predict because it depends on many factors related to the patient and the treatment. In addition, experimental studies indicate that cangrelor may exert a cardioprotective effect beyond the blockade of platelet aggregation. Considering the available data, the potential use of cangrelor in ACS patients goes well beyond the current indications. Furthermore, we believe that it might be prudent to avoid use of thienopyridines during and soon after a cangrelor infusion until conclusive data on the effect of the DDI on the clinical outcome are available. On the other hand, ticagrelor seems to be an optimal oral agent for continuation of P2Y12 inhibition in patients receiving cangrelor infusion.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"83-89"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular sequelae in symptomatic SARS-CoV-2 infection survivors. 有症状的 SARS-CoV-2 感染幸存者的心血管后遗症。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2024-11-07 DOI: 10.5603/cj.99538
Grzegorz Skonieczny, Marta Skowrońska, Agnieszka Dolacińska, Beata Ratajczak, Patrycja Sulik, Oliwia Doroba, Alicja Kotula, Ewelina Błażejowska, Izabela Staniszewska, Olaf Domaszk, Piotr Pruszczyk
{"title":"Cardiovascular sequelae in symptomatic SARS-CoV-2 infection survivors.","authors":"Grzegorz Skonieczny, Marta Skowrońska, Agnieszka Dolacińska, Beata Ratajczak, Patrycja Sulik, Oliwia Doroba, Alicja Kotula, Ewelina Błażejowska, Izabela Staniszewska, Olaf Domaszk, Piotr Pruszczyk","doi":"10.5603/cj.99538","DOIUrl":"10.5603/cj.99538","url":null,"abstract":"<p><strong>Background: </strong>SARS-CoV-2 infection may lead to myocardial and endothelial damage. The present study sought to characterize the cardiovascular sequel in a large group of consecutive patients admitted for out-patient cardiovascular follow-up after a symptomatic COVID-19 infection.</p><p><strong>Methods: </strong>The aims of this study were as follows: to evaluate the presence of post-covid cardiovascular symptoms in an unselected population of outpatients referred to a post-COVID outpatient cardiology clinic and to characterize the long-term abnormalities associated with a more severe COVID-19 infection clinical course. A total of 914 patients were included in this single-center, observational, cross-sectional study, of which 163 were hospitalized and 149 required mechanical ventilation for COVID-19 pneumonia. Patients were analyzed at follow-up according to the care setting during the initial presentation.</p><p><strong>Results: </strong>The median time to follow-up was 126 days. At that time, only 3.5% of patients reported no persistent dyspnea, chest pain, or fatigue on exertion. In a follow-up echocardiographic assessment, patients who required hospitalization showed slight alterations in the pulmonary acceleration time and the tricuspid regurgitation pressure gradient, as well as reduced exercise tolerance during treadmill exercise testing when compared to patients with a benign clinical course. 24-hour Holter EKG monitoring or 24-hour blood pressure monitoring did not identify significant differences between the analyzed subgroups.</p><p><strong>Conclusions: </strong>The current study reports on an association between COVID-19 severity and the presence of cardiovascular alterations at follow-up. A simple diagnostic protocol, comprising an exercise treadmill test and transthoracic echocardiography is useful in identifying patients who may benefit from regular, structured cardiovascular medical care.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes. 经皮冠状动脉介入治疗中的药物包被气球:现有证据和新出现的希望。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2025-04-14 DOI: 10.5603/cj.101393
Aleksandra Gąsecka, Patryk Pindlowski, Mateusz Szczerba, Jakub M Zimodro, Ewelina Błażejowska, Arkadiusz Pietrasik, Maciej Lesiak, Mario Iannaccone, José P S Henriques, René J van der Schaaf, Janusz Kochman
{"title":"Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.","authors":"Aleksandra Gąsecka, Patryk Pindlowski, Mateusz Szczerba, Jakub M Zimodro, Ewelina Błażejowska, Arkadiusz Pietrasik, Maciej Lesiak, Mario Iannaccone, José P S Henriques, René J van der Schaaf, Janusz Kochman","doi":"10.5603/cj.101393","DOIUrl":"10.5603/cj.101393","url":null,"abstract":"<p><p>Drug-coated balloons (DCB) have been developed as an alternative to drug-eluting stents (DES) as a part of the \"leave nothing behind\" strategy following percutaneous coronary interventions (PCI). DCBs facilitate revascularization and delivery of an antiproliferative agent directly to a coronary artery lesion, without the need for DES implantation. Subsequently, DCBs promote positive vascular remodeling and allow for a shorter duration of dual antiplatelet therapy. Since the first reports on the successful treatment of coronary in-stent restenosis (ISR) with paclitaxel-coated balloon catheters in the year 2006, the use of DCBs has been growing, driven by reports of DCB application to treat ISR, bifurcation lesions, and small vessel disease. Contemporary clinical trials evaluating DCBs in large vessel disease and chronic total occlusions might further expand the indications for this technology. Attention has also been brought to the use of DCBs in patients with diabetes mellitus and acute coronary syndrome, especially those at high bleeding risk. This review aims to discuss the existing evidence and emerging hopes associated with DCBs, including technical aspects of DCB PCI and the use of DCBs in different clinical scenarios.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"308-320"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of COVID-19 on the prevalence of bystanders performing cardiopulmonary resuscitation: A systematic review and meta-analysis. COVID-19 对旁观者实施心肺复苏率的影响:系统回顾和荟萃分析。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2024-01-22 DOI: 10.5603/cj.98616
Artur Krawczyk, Krzysztof Kurek, Gabriella Nucera, Michal Pruc, Damian Swieczkowski, Dawid Kacprzyk, Ewa Skrzypek, Nicola Luigi Bragazzi, Kamil Safiejko, Lukasz Szarpak
{"title":"Effect of COVID-19 on the prevalence of bystanders performing cardiopulmonary resuscitation: A systematic review and meta-analysis.","authors":"Artur Krawczyk, Krzysztof Kurek, Gabriella Nucera, Michal Pruc, Damian Swieczkowski, Dawid Kacprzyk, Ewa Skrzypek, Nicola Luigi Bragazzi, Kamil Safiejko, Lukasz Szarpak","doi":"10.5603/cj.98616","DOIUrl":"10.5603/cj.98616","url":null,"abstract":"<p><strong>Background: </strong>The importance of bystander cardiopulmonary resuscitation (CPR) during out-of-hospital cardiac arrests is especially important in the context of coronavirus disease 2029 (COVID-19) because it can significantly influence survival outcomes. The objective of this meta-analysis was to examine the primary outcomes of bystander CPR during the pandemic and pre-pandemic periods.</p><p><strong>Methods: </strong>A search was conducted in the PubMed Central, Scopus, and EMBASE databases, as well as the Cochrane Central Register of Controlled Trials database, up to December 10, 2023. In cases where the value of I² was greater than or equal to 50% or the Q-test indicated that the p-value was less than or equal to 0.05, the studies were considered to be heterogeneous. Sensitivity assessment was performed using the leave-one-out methodology. The study protocol was registered in PROSPERO with the ID number CRD42023494912.</p><p><strong>Results: </strong>Twenty-five articles were included in this meta-analysis. Pooled analysis showed that bystander CPR frequency during the COVID-19 pandemic was 38.8%, compared to 44.8% for the pre-pandemic period (odds ratio: 1.04; 95% confidence interval: 0.93-1.16; p = 0.48).</p><p><strong>Conclusions: </strong>The article's conclusions indicate that the COVID-19 pandemic influenced a reduction in bystander CPR compared to the pre-pandemic period, but this difference was not statistically significant. Further research is recommended to understand attitudes, including the fears of witnesses, before performing CPR on patients with suspected or confirmed infectious diseases. The study highlights the importance of bystander intervention in emergency situations and the impact of a pandemic on public health response behaviors.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"9-18"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An innovative snaring technique to retrieve a dislodged invisible scaffold. 一种创新的捕网技术,用来找回移位的隐形支架。
Cardiology journal Pub Date : 2025-01-01 DOI: 10.5603/cj.103736
Minggang Zhou, Li Chen
{"title":"An innovative snaring technique to retrieve a dislodged invisible scaffold.","authors":"Minggang Zhou, Li Chen","doi":"10.5603/cj.103736","DOIUrl":"https://doi.org/10.5603/cj.103736","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"32 2","pages":"206-207"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diuretic treatment using the RenalGuard® system in patients hospitalized due to acute decompensated heart failure and characterization of the profile of patients with good and poor response to treatment - preliminary study. 使用 RenalGuard® 系统对急性失代偿性心力衰竭住院患者进行利尿治疗,并对治疗效果好和不好的患者进行特征分析--初步研究。
Cardiology journal Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.5603/cj.102386
Paweł Siwołowski, Piotr Gajewski, Mateusz Sokolski, Robert Zymliński, Mateusz Guzik, Joanna Szachniewicz, Piotr Ponikowski
{"title":"Diuretic treatment using the RenalGuard® system in patients hospitalized due to acute decompensated heart failure and characterization of the profile of patients with good and poor response to treatment - preliminary study.","authors":"Paweł Siwołowski, Piotr Gajewski, Mateusz Sokolski, Robert Zymliński, Mateusz Guzik, Joanna Szachniewicz, Piotr Ponikowski","doi":"10.5603/cj.102386","DOIUrl":"10.5603/cj.102386","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to analyze the potential relationship between the diuretic response, the clinical profile and the concentrations of selected biochemical markers and to identify a group of patients who will benefit from a new form of therapy combining standard diuretic therapy with the use of a RenalGuard® system.</p><p><strong>Methods: </strong>This is a retrospective study of 19 patients (mean age 67 ± 10 years, 95% men) hospitalized due to acute decompensated heart failure (ADHF, NYHA class III-IV, BP 125 ± 14/73 ± 16 mmHg, eGFR 58 ± 24) with persistent overhydration despite standard therapy. A targeted comparative analysis of selected clinical and biochemical parameters was performed to determine the parameters associated with a better diuretic response [good diuretic responders (GDR) group].</p><p><strong>Results: </strong>The good diuretic responders group had significantly lower levels of creatinine (1.23 ± 0.4 vs. 1.69 ± 0.35, p = 0.025) magnesium 0.70 ± 0.14 vs. 0.83 ± 0.09, p = 0.030) and blood urea nitrogen (BUN, 28 ± 11 vs. 39 ± 10, p = 0.045). Additionally, in GDR group a statistically significant greater ability to dilute urine in the 12th and 24th hour of therapy was found.</p><p><strong>Conclusions: </strong>The results of the study indicate the potential use of the RenalGuard® system in combination with standard intravenous diuretic therapy for controlled dehydration in the treatment of a selected group of patients with ADHF. It is advisable to identify the detailed mechanisms of GDR and characterize this group of patients more precisely.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"43-52"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信